Nicotinamide N-methyltransferase expression in SH-SY5Y neuroblastoma and N27 mesencephalic neurones induces changes in cell morphology via ephrin-B2 and Akt signalling

Cell Death and Disease

Volumn 4, Issue 6, 2013, Pages

  Thomas, M G ^a   Saldanha, M ^a   Mistry, R J ^a   Dexter, D T ^b   Ramsden, D B ^c   Parsons, R B ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

cell signalling; neurone differentiation; nicotinamide N methyltransferase; phenotypic markers

Indexed keywords

1 METHYLNICOTINAMIDE; DOPAMINE; EPHRIN B2; NICOTINAMIDE METHYLTRANSFERASE; PROTEIN KINASE B; SMALL INTERFERING RNA; SYNAPTOPHYSIN;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CELL FATE; CELL STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MESENCEPHALON; MOUSE; NERVE CELL CULTURE; NERVE CELL DIFFERENTIATION; NERVE FIBER GROWTH; NEUROBLASTOMA; NEUROBLASTOMA CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; RAT;

RATTUS;

EID: 84879678668     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.200     Document Type: Article

References (51)

1. Aksoy S, Szumlanski CL, Weinshilboum RM. Human liver nicotinamide N-methyltransferase. cDNA cloning, expression, and biochemical characterisation. J Biol Chem 1994; 269: 14835-14840.
2. Parsons RB, Smith ML, Williams AC, Ramsden DB. Expression of nicotinamide N-methyltransferase (E.C. 2.1.1.1) in the Parkinsonian brain. J Neurol Exp Neurol 2002; 61: 111-124.
3. Kassem HS, Sangar V, Cowan R, Clarke N, Margison GP. A potential role of heat shock proteins and nicotinamide N-methyltransferase in predicting response to radiation in bladder cancer. Int J Cancer 2002; 101: 454-460.
4. Roessler M, Rollinger W, Palme S, Hagmann ML, Berndt P, Engel AM et al. Identification of nicotinamide N-methyltransferase as a novel serum tumour marker for colorectal cancer. Clin Cancer Res 2005; 11: 6550-6557.
5. Tomida M, Ohtake H, Yokota T, Kobayashi Y, Kurosumi M. Stat3 up-regulates expression of nicotinamide N-methyltransferase in human cancer cells. J Cancer Res Clin Oncol 2008; 134: 551-559.
6. Kim J, Hong SJ, Lim EK, Yu YS, Kim SW, Roh JH et al. Expression of nicotinamide N-methyltransferase in hepatocellular carcinoma is associated with poor prognosis. J Exp Clin Cancer Res 2009; 28: 20.
7. Emanuelli M, Santarelli A, Sartini D, Ciavarella D, Rossi V, Pozzi V et al. Nicotinamide N-methyltransferase upregulation correlates with tumour differentiation in oral squamous cell carcinoma. Histol Histopathol 2010; 25: 15-20.
8. Sternak M, Khomich TI, Jakubowski A, Szafarz M, Szczepań ski W, Biaas M et al. Nicotinamide N-methyltransferase (NNMT) and 1-methylnicotinamide (MNA) in experimental hepatitis induced by concanavalin A in the mouse. Pharmacol Rep 2010; 62: 483-493.
9. Kim HC, Mofarrahi M, Vassilakopoulos T, Maltais F, Sigala I, Debigare R et al. Expression and functional significance of nicotinamide N-methyltransferase in skeletal muscle of patients with chronic obstructive pulmonary disease. Am J Respir Care Med 2010; 181: 797-805.
10. Parsons RB, Smith SW, Waring RH, Williams AC, Ramsden DB. High expression of nicotinamide N-methyltransferase in patients with idiopathic Parkinson's disease. Neurosci Lett 2003; 342: 13-16.
11. Parsons RB, Aravindan S, Kadampeswaran A, Evans EA, Sandhu KK, Levy ER et al. The expression of nicotinamide N-methyltransferase increases ATP synthesis and protects SHSY5Y human neuroblastoma cells against the toxicity of Complex I inhibitors. Biochem J 2011; 436: 145-155.
12. Tang SW, Yang TC, Lin WC, Chang WH, Wang CC, Lai MK et al. Nicotinamide N-methyltransferase induces cellular invasion though activating matrix metalloproteinase-2 expression in clear renal cell carcinoma cells. Carcinogenesis 2011; 32: 138-145.
13. Fredrich M, Illing RB. MMP-2 is involved in synaptic remodelling after cochlear lesion. Neuroreport 2010; 21: 324-327.
14. Song G, Ouyang G, Bao S. The activation of Akt/PKB signalling pathway and cell survival. J Cell Mol Med 2005; 9: 59-71.
15. Burke RE. Inhibition of mitogen-activated protein kinase and stimulation of Akt kinase signalling pathways: two approaches with therapeutic potential in the treatment of neurodegenerative disease. Pharmacol Ther 2007; 114: 261-277.
16. Levy OA, Malagelada C, Greene LA. Cell death pathways in Parkinson's disease: proximal triggers, distal effectors and final steps. Apoptosis 2009; 14: 478-500.
17. Namikawa K, Honma M, Abe K, Takeda M, Mansur K, Obata T et al. Akt/protein kinase B prevents injury-induced motor neuron death and accelerates neuronal regeneration. J Neurosci 2000; 20: 2875-2886.
18. Du Y, Li X, Yang D, Zhang X, Chen S, Huang K et al. Multiple molecular pathways are involved in the neuroprotection of GDNF against proteasome inhibitor induced dopamine neuron degeneration in vivo. Exp Biol Med (Maywood) 2008; 233: 881-890.
19. Timmons S, Coakley MF, Moloney AM, O'Niel C. Akt signal transduction dysfunction in Parkinson's disease. Neurosci Lett 2009; 467: 30-35.
20. Cheung YT, Lau WK, Yu MS, Lai CS, Yeung SC, So KF et al. Effects of all-trans-retinoic acid on human SH-SY5Y neuroblastoma as in vitro model in neurotoxicity research. Neurotoxicology 2009; 30: 127-135.
21. Malagelada C, Jin D, Greene LA. RTP-801 is induced in Parkinson's disease and mediates neuron death by inhibiting Akt phosphorylation/activation. J Neurosci 2008; 28: 14363-14371.
22. Sagi Y, Mandel S, Amit T, Youdim MB. Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism. Neurobiol Dis 2007; 25: 35-44.
23. Steinle JJ, Meininger CJ, Forough R, Wu G, Wu MH, Granger HJ. Eph B4 receptor signaling mediates endothelial cell migration and proliferation via the phosphatidylinositol 3-kinase pathway. J Biol Chem 2002; 277: 43830-43835.
24. Feldmann G, Habbe N, Dhara S, Bisht S, Alvarez H, Fendrich V et al. Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer. Gut 2008; 57: 1420-1430.
25. Georgakopoulos A, Xu J, Xu C, Mauger G, Barthet G, Robakis NK. Presenilin1/gammasecretase promotes the EphB2-induced phosphorylation of ephrinB2 by regulating phosphoprotein associated with glycosphingolipid-enriched microdomains/Csk binding protein. FASEB J 2011; 25: 3594-3604.
26. Dalva MB, Takasu MA, Lin MZ, Shamah SM, Hu L, Gale NW et al. EphB receptors interact with NMDA receptors and regulate excitatory synapse formation. Cell 2000; 103: 945-956.
27. Henkemeyer M, Itkis OS, Ngo M, Hickmott PW, Ethell IM. Multiple EphB receptor tyrosine kinases shape dendritic spines in the hippocampus. J Cell Biol 2003; 163: 1313-1326.
28. McClelland AC, Sheffler-Collins SI, Kayser MS, Dalva MB. Ephrin-B1 and ephrin-B2 mediate EphB-dependent presynaptic development via syntenin-1. Proc Natl Acad Sci USA 2009; 106: 20487-20492.
29. Chen Y, Fu WY, Ip JP, Ye T, Fu AK, Chao MV et al. Ankyrin repeat-rich membrane spanning protein (kidins220) is required for neurotrophin and ephrin receptor-dependent dendrite development. J Neurosci 2012; 32: 8263-8269.
30. Sloniowski S, Ethell IM. Looking forward to EphB signaling in synapses. Semin Cell Dev Bio 2012; 23: 75-82.
31. Perović M, Mladenović A, Rakić L, Ruzdijić S, Kanazir S. Increase of GAP-43 in the rat cerebellum following unilateral striatal 6-OHDA lesion. Synapse 2005; 56: 170-174.
32. Hayes L, Ralls S, Wang H, Ahn S. Duration of Shh signaling contributes to mDA neuron diversity. Dev Biol 2013; 374: 115-126.
33. Ran X, Qin H, Liu J, Fan JS, Shi J, Song J. NMR structure and dynamics of human ephrin-B2 ectodomain: the functionally critical C-D and G-H loops are highly dynamic in solution. Proteins 2008; 72: 1019-1029.
34. Yavrouian EJ, Sinha UK, Rice DH, Salam MT, Gill PS, Masood R. The significance of ephB4 and ephrinB2 expression and survival in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2008; 134: 985-991.
35. Ishii K, Oda Y, Ichikawa T, Deguchi T. Complementary DNAs for choline acetyltransferase from spinal cords of rat and mouse: nucleotide sequences, expression in mammalian cells, and in situ hybridization. Brain Res Mol Brain Res 1990; 7: 151-159.
36. Oda Y, Nakanishi I, Deguchi T. A complementary DNA for human choline acetyltransferase induces two forms of enzyme with different molecular weights in cultured cells. Brain Res Mol Brain Res 1992; 16: 287-294.
37. Kim KK, Adelstein RS, Kawamoto S. Identification of neuronal nuclei (NeuN) as Fox-3, a new member of the Fox-1 gene family of splicing factors. J Biol Chem 2009; 284: 31052-31061.
38. Sarkanen JR, Nykky J, Siikanen J, Selinummi J, Ylikomi T, Jalonen TO. Cholesterol supports the retinoic acid-induced synaptic vesicle formation in differentiating human SH-SY5Y neuroblastoma cells. J Neurochem 2007; 102: 1941-1952.
39. Xie HR, Hu LS, Li GY. SH-SY5Y human neuroblastoma cell-line: in vitro cell model of dopaminergic neurons in Parkinson's disease. Chin Med J (Engl) 2010; 123: 1086-1092.
40. Encinas M, Iglesias M, Liu Y, Wang H, Muhaisen A, Ceña V et al. Sequential treatment of SH-SY5Y cells with retinoic acid and brain-derived neurotrophic factor gives rise to fully differentiated, neurotrophic factor-dependent, human neuron-like cells. J Neurochem 2000; 75: 991-1003.
41. Agholme L, Lindström T, Kägedal K, Marcusson J, Hallbeck M. An in vitro model for neuroscience: differentiation of SH-SY5Y cells into cells with morphological and biochemical characteristics of mature neurons. J Alzheimers Dis 2010; 20: 1069-1082.
42. Kanthasamy AG, Anantharam V, Zhang D, Latchoumycandane C, Jin H, Kaul S et al. A novel peptide inhibitor targeted to caspase-3 cleavage site of a proapoptotic kinase protein kinase C delta (PKCd) protects against dopaminergic neuronal degeneration in Parkinson's disease models. Free Radic Biol Med 2006; 41: 1578-1589.
43. Zhou W, Bercury K, Cummiskey J, Luong N, Lebtin J, Freed CR. Phenylbutyrate up-regulates the DJ-1 protein and protects neurones in cell culture and in animal models of Parkinson disease. J Biol Chem 2011; 286: 14941-14951.
44. Adams FS, La Rosa FG, Kumar S, Edwards-Prasad J, Kentroti S, Vernadakis A et al. Characterisation and implantation of two neuronal cell-lines with dopaminergic properties. Neurochem Res 1996; 21: 619-627.
45. Fukushima T, Tawara T, Isobe A, Hojo N, Shiwaku K, Yamane Y. Radical formation site of cerebral Complex I and Parkinson's disease. J Neurosci Res 1995; 42: 385-390.
46. Fukushima T, Kaetsu A, Lim H, Moriyama M. Possible role of 1-methylnicotinamide in the pathogenesis of Parkinson's disease. Exp Toxicol Pathol 2002; 53: 469-473.
47. Mori Y, Sugawara A, Tsuji M, Kakamu T, Tsuboi S, Kanda H et al. Toxic effects of nicotinamide methylation on mouse brain striatum neuronal cells and its relation to manganese. Environ. Health Prev Med 2012; 17: 371-376.
48. Williams AC, Ramsden DB. Autotoxicity, methylation and a road to the prevention of Parkinson's disease. J Clin Neurosci 2005; 12: 6-11.
49. Lam PM, Hainsworth AH, Smith GD, Owen DE, Davies J, Lambert DG. Activation of recombinant human TRPV1 receptors expressed in SH-SY5Y human neuroblastoma cells increases [Ca(2\+)](i), initiates neurotransmitter release and promotes delayed cell death. J Neurochem 2007; 102: 801-811.
50. Jiang H, Jiang Q, Feng J. Parkin increases dopamine uptake by enhancing the cell surface expression of dopamine transporter. J Biol Chem 2004; 279: 54380-54386.
51. Ault DT, Werling LL. SH-SY5Y cells as a model for sigma receptor regulation of potassiumstimulated dopamine release. Brain Res 2000; 877: 354-360.